The nociceptin/orphanin FQ peptide (NOP, ORL1, or OP4) receptor is a member of the opioid family of receptors that integrates the emotional components of anxiety, fear, and stress. MCOPPB is a potent agonist for the NOP receptor (pKi = 10.1, EC50 = 0.39 nM) with 12-, 270-, and >1,000-fold selectivity over the μ-, κ-, and δ-opioid receptors.1,2 In rodents, MCOPPB at 10 mg/kg, p.o. produces potent anxiolytic effects, without inhibiting memory or motor function or inducing sedative side effects.1 This product is intended for research purposes only.WARNING This product is not for human or veterinary use.
[1] AKIKO HIRAO . Pharmacological Characterization of the Newly Synthesized Nociceptin/Orphanin FQ–Receptor Agonist 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R )-3-piperidinyl]-1H-benzimidazole as an Anxiolytic Agent[J]. Journal of pharmacological sciences, 2008, 106 3: Pages 361-368. DOI:
10.1254/jphs.fp0071742[2] SHIGEO HAYASHI*. Novel Non-Peptide Nociceptin/Orphanin FQ Receptor Agonist, 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole: Design, Synthesis, and Structure−Activity Relationship of Oral Receptor Occupancy in the Brain for Orally Potent Antianxiety Drug(1, 2)[J]. Journal of Medicinal Chemistry, 2009, 52 3: 610-625. DOI:
10.1021/jm7012979
